All News

Every healthcare company should be striving to identify better ways to ensure patients and consumers inspire every decision they make, writes Joanne Waldstreicher.

Do’s and Dont’s while facing the increased war for talent.

A 2019 study reveals further marginal decline in the pharma industry's reputation. Sven Klingemann suggests some "recovery solutions".

A look at questions that need to be answered regarding drug importation coexisting with the Drug Supply Chain Security Act (DSCSA).

Click the title above to open the Pharmaceutical Executive August 2019 issue in an interactive PDF format.

With Spain enjoying an economic rebound, pharma and medtech multinationals are seeing the country as a top-tier investment destination once more-thanks to improved market access, quality but affordable manufacturing capabilities, and an enviable clinical research base.

Highlighting the biggest observations from this year's DIA Annual Meeting-topics likely to continue to dominate industry headlines for the foreseeable future.

Click the title above to open the Pharmaceutical Executive July 2019 issue in an interactive PDF format.

In the middle of new reforms, and with its political turmoil well in the past, Egypt is striving to open the door to a brave new era of healthcare provision, where improving public healthcare has been assigned priority status.

The opportunities and challenges surrounding patient centricity and patient-centric trials in China.

Our latest rankings and report of the top 50 biopharma companies provides a nice springboard to the coverage we have in store for you in the year's second half.

Successor to current CEO Olivier Brandicourt is announced.

Nominations for the 2019 eyeforpharma awards are currently open.

Pharmaceutical manufacturers should plan for a DTC strategy to minimize the risk of patient abandonment due to pricing concerns.

Click the title above to open the Pharmaceutical Executive June 2019 issue in an interactive PDF format.

After several years of losing pace to many of its European peers when it comes to pharma production and R&D, France’s life sciences market, sparked by a renewed spirit of reform, is now squarely back on the radar of the international investor community.

Intellectual property attorneys discuss the clarified requirements for when state failure-to-warn claims are pre-empted by FDA regulations after the Supreme Court Merck case.